Xeris Pharmaceuticals

Xeris Pharmaceuticals, now known as Xeris Biopharma Holdings, Inc., is a biopharmaceutical company based in Chicago, Illinois. Founded in 2005 by Steve Prestrelski and John Kinzell, Xeris focuses on developing and commercializing advanced therapeutic products, particularly through innovative drug delivery technologies. The company aims to enhance patient convenience and treatment efficacy with its ready-to-use injectable formulations. Xeris's product portfolio includes Gvoke, an FDA-approved glucagon injection for treating severe hypoglycemia in diabetes patients, and therapies for primary periodic paralysis and Cushing's syndrome. The company expanded its offerings through the acquisition of Strongbridge Biopharma in 2020, which added rare disease products to its lineup. Xeris holds 40 patents and has proprietary formulation technology for sustained-release therapeutic compositions. The company went public in 2018 and continues to pursue strategic collaborations to advance its innovative therapies.

Partnerships